Dockets Management Branch The Food and Drug Administration Department of Health & Human Services, Rm. 1-23 12420 Parklawn Dr. Rockville, MD 20857		Date:	
Re: 99P-1340/CP 1 — Petition	to Have Eternity eau de pa	rfum declared "Misbanded	" JUL 21 P1:49
Dear Sir or Madam:			
In May 1999, the Environmental Health Network (EHN) submitted the above petition to have Calvin Klein's <i>Eternity</i> eau de parfum declared "misbranded." I am writing because I fully support this petition and request that the FDA give it careful attention with regard to your regulations 21CFR Sec. 740.1, 21CFR Sec. 740.2, and 21CFR Sec. 740.10. Regulation 21CFR Sec. 740.10 states:			
Each ingredient used in a cosmetic product and each finished cosmetic product shall be adequately substantiated for safety prior to marketing. Any such ingredient or product whose safety is not adequately substantiated prior to marketing is misbranded unless it contains the following conspicuous statement on the principal display panel:			
	• • •	roduct has not been determi	
As the petition shows, <i>Eternity</i> contains toxic ingredients and ingredients whose safety have not been substantiated. There is no warning label on its packaging.			
We all have a right to know the status of safety testing of the ingredients in products such as <i>Eternity</i> so that we can protect ourselves and our families from toxic chemicals that may cause health problems. Most people are not aware that most fragrance materials have only limited safety testing. They wrongfully assume these products are safe to use in any setting and are surprised when people complain.			
Like tobacco smoke, the har people, including: people with es. Children are particularly v parents, caregivers and teache ing symptoms based upon the	n asthma, chemical sensitul ulnerable to toxic chemic ers. When I am exposed to	ivities, chronic fatigue, and o als found in products purch o fragrance products I can e	other environmental illness- ased and used by their
□ anaphylaxis/shock □	double vision	☐ incoherence	□ nausea
☐ anxiety, restlessness ☐	ear pain	☐ incontinence	nose bleeds
🙎 asthma 🔠	eczema	☐ irritability	☐ rashes
	eyes, watery or dry	joint aches	☐ seizures
☐ bronchitis ☐	fatigue	☐ laryngitis	short-term mem. loss
☐ can't concentrate ☐	flushing	☐ lethargy	-sinusitis
oughing  depression	headaches	lymph nodes swell	☐ sneezing
☐ depression ☐ ☐ disorientation ☐	heart beat irregularity hives	mood swings  muscle pain/weaknes	☐ sores, skin/mouth ss ☐ swallowing difficulty
dizziness	hypertension	nasal congestion	innitus
other:			
P-13 40	.:11: ( l l l	a	
Please act on behalf of the magrance exposure at work, at people disabled by asthma and countless lives. Thank you.  Sincerely,	school and in social setti	ngs. These toxic chemicals a	act as powerful barriers to
SUSAN LEUINKINY)			
address; city/st/zip	ST, OAKLAN	D, CA 94605	

first, fold down





HFA 305

Attn: 99P-1340|CP1

Dockets Management Branch
The Food and Drug Administration
Department of Health & Human Services, Rm. 1-23
12420 Parklawn Dr.
Rockville, MD 20857

Indelling of the defendant of the

second, fold up